Parareg

USDailyMed:Cinacalcet AU:B3 H05BX01(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) (R)-N-[1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine 226256-56-0Y 156419 46506315 3308 DB01012Y 137743Y UAZ6V7728S D03504YD03505Y CHEBI:48390Y ChEMBL1201284N DTXSID8048286 Interactive image CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1YKey:VDHAWDNDOKGFTD-MRXNPFEDSA-NY Cinacalcet, sold under the brand nameSensiparamong others, is a medication used to treatprimary hyperparathyroidism,tertiary hyperparathyroidismandparathyroid carcinoma.Cinacalcet acts as acalcimimetic(i.e., it mimics the action ofcalciumontissues) byallostericactivation of thecalcium-sensing receptorthat is expressed in various human organ tissues. The most common side effects includenauseaandvomiting. Cinacalcet was approved in the United States in March 2004,and in the European Union in October 2004.It was the first allosteric G protein-coupled receptor modulator to enter the pharmaceutical market.In 2013, cinacalcet was the 76th most prescribed medicine in the United States.